Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 170 JPY -0.58% Market Closed
Market Cap: 15.3B JPY
Have any thoughts about
Healios KK?
Write Note

Healios KK
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Healios KK
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Healios KK
TSE:4593
Operating Income
-ÂĄ3.1B
CAGR 3-Years
16%
CAGR 5-Years
5%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Operating Income
ÂĄ8.6B
CAGR 3-Years
53%
CAGR 5-Years
48%
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Operating Income
ÂĄ24.5B
CAGR 3-Years
39%
CAGR 5-Years
49%
CAGR 10-Years
70%
Takara Bio Inc
TSE:4974
Operating Income
ÂĄ2B
CAGR 3-Years
-56%
CAGR 5-Years
-17%
CAGR 10-Years
-1%
Pharma Foods International Co Ltd
TSE:2929
Operating Income
ÂĄ5.2B
CAGR 3-Years
-16%
CAGR 5-Years
95%
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Operating Income
-ÂĄ588.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Healios KK
Glance View

Market Cap
15.3B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
142.38 JPY
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Healios KK's Operating Income?
Operating Income
-3.1B JPY

Based on the financial report for Sep 30, 2024, Healios KK's Operating Income amounts to -3.1B JPY.

What is Healios KK's Operating Income growth rate?
Operating Income CAGR 5Y
5%

Over the last year, the Operating Income growth was 9%. The average annual Operating Income growth rates for Healios KK have been 16% over the past three years , 5% over the past five years .

Back to Top